No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
REVB Revelation Biosciences
- 0.2950
- -0.0196-6.23%
Close Dec 20 16:00 ET
- 0.3005
- +0.0055+1.86%
Post 20:01 ET
1.91MMarket Cap-0.02P/E (TTM)
0.3180High0.2950Low477.71KVolume0.3100Open0.3146Pre Close145.73KTurnover11.14%Turnover RatioLossP/E (Static)6.46MShares25.260052wk High0.71P/B1.26MFloat Cap0.295052wk Low--Dividend TTM4.29MShs Float11854.5000Historical High--Div YieldTTM7.31%Amplitude0.2950Historical Low0.3050Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Revelation Biosciences Files for Shelf of up to 14.2 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Sector Update: Health Care
Top Midday Decliners
Why Revelation Biosciences (REVB) Stock Is Down 38%
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
The FDA Has Accepted Revelation Biosciences' Investigational New Drug Application To Initiate Phase 1b Study To Evaluate Gemini As A Preconditioning Treatment In Chronic Kidney Disease Patients, Study To Start In Early 2025
Heat List
US
Overall
Symbol
Price
% Chg
No Data